Compare · EYPT vs MTD
EYPT vs MTD
Side-by-side comparison of EyePoint Inc. (EYPT) and Mettler-Toledo International Inc. (MTD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYPT and MTD operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- MTD is the larger of the two at $32.84B, about 121.3x EYPT ($270.7M).
- MTD has been more active in the news (2 items in the past 4 weeks vs 1 for EYPT).
- MTD has more recent analyst coverage (25 ratings vs 16 for EYPT).
- Company
- EyePoint Inc.
- Mettler-Toledo International Inc.
- Price
- -
- -
- Market cap
- $270.7M
- $32.84B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 1
- 2
- Recent ratings
- 16
- 25
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Mettler-Toledo International Inc.
Mettler-Toledo International Inc. manufactures and supplies precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company offers weighing instruments for laboratory, industrial, packaging, logistics, and food retailing applications; various related analytical instruments and automated chemistry solutions used in drug and chemical compound discovery and development; metal detection and other end-of-line product inspection systems used in production and packaging for food processing and packaging, pharmaceutical, packaged consumer goods, and other industries; and solutions that are used in various process analytics applications. Its laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform. The company's industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, and product inspection systems. Its retail weighing solutions consist of networked scales and software, and stand-alone scales for handling fresh goods, such as meats, vegetables, fruits, and cheeses. The company serves the life science industry, and independent research organizations; food and beverage producers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community. It markets its products through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
Latest EYPT
- Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form SCHEDULE 13G filed by EyePoint Inc.
- EyePoint downgraded by TD Cowen with a new price target
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
- Chief Financial Officer Elston George acquired 5,000 shares, gifted 64,953 shares, received a gift of 64,953 shares and disposed of 5,000 shares, decreasing direct ownership by 65% to 32,517 units (SEC Form 4)
- Director Zaderej Karen L. bought $52,258 worth of shares (10,600 units at $4.93), increasing direct ownership by 28% to 49,100 units (SEC Form 4)
- EyePoint downgraded by Chardan Capital Markets with a new price target
- EyePoint downgraded by RBC Capital Mkts with a new price target
Latest MTD
- Mettler-Toledo International Inc. to Host Investor Meeting
- Mettler-Toledo International Inc. to Host Third Quarter 2026 Earnings Conference Call
- UBS resumed coverage on Mettler-Toledo with a new price target
- Rothschild & Co Redburn initiated coverage on Mettler-Toledo with a new price target
- Director Shuman-Fabbri Natalia was granted 16 shares (SEC Form 4)
- RBC Capital Mkts initiated coverage on Mettler-Toledo with a new price target
- President and CEO Kaltenbach Patrick exercised 942 shares at a strike of $1,024.55 and sold $1,342,350 worth of shares (942 units at $1,425.00) (SEC Form 4)
- Director Salice Thomas P exercised 417 shares at a strike of $397.95 and sold $600,651 worth of shares (417 units at $1,440.41) (SEC Form 4)
- Director Salice Thomas P exercised 415 shares at a strike of $397.95 and sold $599,517 worth of shares (415 units at $1,444.62) (SEC Form 4)
- Head of Process Analytics Keller Gerry exercised 240 shares at a strike of $720.81 and sold $342,514 worth of shares (240 units at $1,427.14) (SEC Form 4)